Pharmacogenomics of Oral Antiplatelet Drugs

• Ancrenaz V , DaaliY, FontanaP et al. Impact of genetic polymorphisms and drug–drug interactions on clopidogrel and prasugrel response variability. Curr. Drug Metab. 11(8) , 667–677 (2010).
   PubMed Web of Science ®Google Scholar
• Fintel DJ . Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. Vasc. Health Risk Manag.8 , 77–89 (2012).
   PubMedGoogle Scholar
• Jennings LK . Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb. Haemost.102(2) , 248–257 (2009).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ . The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs72(16) , 2087–2116 (2012).
   PubMed Web of Science ®Google Scholar
• Gresele P , MomiS, FalcinelliE. Anti-platelet therapy: phosphodiesterase inhibitors. Br. J. Clin. Pharmacol.72(4) , 634–646 (2011).
   PubMed Web of Science ®Google Scholar
• Perk J , De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur. Heart J.33(13) , 1635–1701 (2012).
   PubMed Web of Science ®Google Scholar
• Ahmad T , VooraD, BeckerRC. The pharmacogenetics of antiplatelet agents: towards personalized therapy? Nat. Rev. Cardiol.8(10) , 560–571 (2011).
   PubMed Web of Science ®Google Scholar
• Lanham KJ , OestreichJH, DunnSP, SteinhublSR. Impact of genetic polymorphisms on clinical response to antithrombotics. Pharmgenomics Pers. Med.3 , 87–99 (2010).
   PubMedGoogle Scholar
• Awidi A , SalehA, DweikM et al. Measurement of platelet reactivity of patients with cardiovascular disease on-treatment with acetyl salicylic acid: a prospective study. Heart Vessels 26(5) , 516–522 (2011).
   PubMed Web of Science ®Google Scholar
• Goodman T , FerroA, SharmaP. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br. J. Clin. Pharmacol.66(2) , 222–232 (2008).
   PubMed Web of Science ®Google Scholar
• Feher G , FeherA, PuschG, LupkovicsG, SzaparyL, PappE. The genetics of antiplatelet drug resistance. Clin. Genet.75(1) , 1–18 (2009).
   PubMed Web of Science ®Google Scholar
• Abderrazek F , ChakrounT, AddadF et al. The GPIIIa PlA polymorphism and the platelet hyperactivity in Tunisian patients with stable coronary artery disease treated with aspirin. Thromb. Res. 125(6) , e265–e268 (2010).
   PubMed Web of Science ®Google Scholar
• Lordkipanidzé M , DiodatiJG, PalisaitisDA, SchampaertE, TurgeonJ, PharandC. Genetic determinants of response to aspirin: appraisal of 4 candidate genes. Thromb. Res.128(1) , 47–53 (2011).
   PubMed Web of Science ®Google Scholar
• Kastrati A , KochW, GawazM et al. PlA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement. J. Am. Coll. Cardiol.36(1) , 84–89 (2000).
   PubMed Web of Science ®Google Scholar
• Voora D , HortonJ, ShahSH, ShawLK, NewbyLK. Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use. Am. Heart J.162(1) , 166–172 (2011).
   PubMed Web of Science ®Google Scholar
• Clappers N , van Oijen MG, Sundaresan S et al. The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb. Haemost.100(1) , 70–75 (2008).
   PubMed Web of Science ®Google Scholar
• Jefferson BK , FosterJH, McCarthyJJ et al. Aspirin resistance and a single gene. Am. J. Cardiol. 95(6) , 805–808 (2005).
   PubMed Web of Science ®Google Scholar
• Xu ZH , JiaoJR, YangR, LuoBY, WangXF, WuF. Aspirin resistance: clinical significance and genetic polymorphism. J. Int. Med. Res.40(1) , 282–292 (2012).
   PubMed Web of Science ®Google Scholar
• Fan L , CaoJ, LiuL et al. Frequency, risk factors, prognosis, and genetic polymorphism of the cyclooxygenase-1 gene for aspirin resistance in elderly Chinese patients with cardiovascular disease. Gerontology 59(2) , 122–131 (2013).
   PubMed Web of Science ®Google Scholar
• Maree AO , CurtinRJ, ChubbA et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J. Thromb. Haemost. 3(10) , 2340–2345 (2005).
   PubMed Web of Science ®Google Scholar
• Lemaitre RN , RiceK, MarcianteK et al. Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. Atherosclerosis 204(2) , e58–e63 (2009).
   PubMedGoogle Scholar
• Bierend A , RauT, MaasR, SchwedhelmE, BogerRH. P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease. Br. J. Clin. Pharmacol.65(4) , 540–547 (2008).
   PubMed Web of Science ®Google Scholar
• Timur AA , MurugesanG, ZhangL et al. P2RY1 and P2RY12 polymorphisms and on-aspirin platelet reactivity in patients with coronary artery disease. Int. J. Lab. Hematol.34(5) , 473–483 (2012).
   PubMed Web of Science ®Google Scholar
• Kunicki TJ , WilliamsSA, NugentDJ et al. Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease. Thromb. Haemost. 101(1) , 123–133 (2009).
   PubMed Web of Science ®Google Scholar
• Gurbel PA , ShuldinerAR, BlidenKP, RyanK, PakyzRE, TantryUS. The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. Am. Heart J.161(3) , 598–604 (2011).
   PubMed Web of Science ®Google Scholar
• Lepäntalo A , MikkelssonJ, ResendizJC et al. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb. Haemost. 95(2) , 253–259 (2006).
   PubMed Web of Science ®Google Scholar
• Macchi L , ChristiaensL, BrabantS et al. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibα) polymorphisms. J. Am. Coll. Cardiol. 42(6) , 1115–1119 (2003).
   PubMed Web of Science ®Google Scholar
• Postula M , Kaplon-CieslickaA, RosiakM et al. Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: evaluation of 27 polymorphisms within candidate genes. J. Thromb. Haemost. 9(11) , 2291–2301 (2011).
   PubMed Web of Science ®Google Scholar
• Gao F , WangZX, MenJL, RenJ, WeiMX. Effect of polymorphism and Type II diabetes on aspirin resistance in patients with unstable coronary artery disease. Chin. Med. J. (Engl.)124(11) , 1731–1734 (2011).
   PubMed Web of Science ®Google Scholar
• Herrera-Galeano JE , BeckerDM, WilsonAF et al. A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet agreeability. Arterioscler. Thromb. Vasc. Biol. 28(8) , 1484–1490 (2008).
   PubMed Web of Science ®Google Scholar
• Lewis JP , RyanK, O‘ConnellJR et al. Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Circ. Cardiovasc. Genet. 6(2) , 184–192 (2013).
   PubMed Web of Science ®Google Scholar
• Chasman DI , ShiffmanD, ZeeRY et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis 203(2) , 371–376 (2009).
   PubMed Web of Science ®Google Scholar
• Farid NA , KuriharaA, WrightonSA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J. Clin. Pharmacol.50(2) , 126–142 (2010).
   PubMed Web of Science ®Google Scholar
• Yusuf S , ZhaoF, MehtaSR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7) , 494–502 (2001).
   PubMed Web of Science ®Google Scholar
• Fox K , GarciaMA, ArdissinoD et al. Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European Society of Cardiology. Eur. Heart J. 27(11) , 1341–1381 (2006).
   PubMed Web of Science ®Google Scholar
• Hamm CW , BassandJP, AgewallS et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 32(23) , 2999–3054 (2011).
   PubMed Web of Science ®Google Scholar
• Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J.33(20) , 2569–2619 (2012).
   PubMed Web of Science ®Google Scholar
• Fihn SD , GardinJM, AbramsJ et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College Of Cardiology Foundation/American Heart Association Task Force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society Of Thoracic Surgeons. Circulation 126(25) , 3097–3137 (2012).
   PubMed Web of Science ®Google Scholar
• Camilleri E , JacquinL, PaganelliF, BonelloL. Personalized antiplatelet therapy: review of the latest clinical evidence. Curr. Cardiol. Rep.13(4) , 296–302 (2011).
   PubMedGoogle Scholar
• Cavallari LH , JeongH, BressA. Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers. Med.4 , 123–136 (2011).
   PubMedGoogle Scholar
• Donohue MM , TirschwellDL. Implications of pharmacogenetic testing for patients taking warfarin or clopidogrel. Curr. Neurol. Neurosci. Rep.11(1) , 52–60 (2011).
   PubMed Web of Science ®Google Scholar
• Ellis KJ , StoufferGA, McLeodHL, LeeCR. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics10(11) , 1799–1817 (2009).
   PubMed Web of Science ®Google Scholar
• Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, Writing Committee Members et al. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation122(5) , 537–557 (2010).
   PubMed Web of Science ®Google Scholar
• Ned RM . Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics. PLoS Curr.2(pii) , RRN1180 (2010).
   PubMedGoogle Scholar
• Dahl ML , GunesA. Implications of inter-individual differences in clopidogrel metabolism, with focus on pharmacogenetics. Pharmaceuticals3(4) , 782–794 (2010).
   Google Scholar
• Bauer T , BoumanHJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ343 , d4588 (2011).
   PubMed Web of Science ®Google Scholar
• Zabalza M , SubiranaI, SalaJ et al. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 98(2) , 100–108 (2012).
   PubMed Web of Science ®Google Scholar
• Mega JL , SimonT, ColletJP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304(16) , 1821–1830 (2010).
   PubMed Web of Science ®Google Scholar
• Sofi F , GiustiB, MarcucciR, GoriAM, AbbateR, GensiniGF. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J.11(3) , 199–206 (2011).
   PubMed Web of Science ®Google Scholar
• Jang JS , ChoKI, JinHY et al. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. Am. J. Cardiol. 110(4) , 502–508 (2012).
   PubMed Web of Science ®Google Scholar
• Hulot JS , ColletJP, SilvainJ et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor co-administration: a systematic meta-analysis. J. Am. Coll. Cardiol. 56(2) , 134–143 (2010).
   PubMed Web of Science ®Google Scholar
• Jin B , NiHC, ShenW, LiJ, ShiHM, LiY. Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel. Mol. Biol. Rep.38(3) , 1697–1702 (2011).
   PubMed Web of Science ®Google Scholar
• Liu YP , HaoPP, ZhangMX et al. Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: an updated meta-analysis. Thromb. Res. 128(6) , 593–594 (2011).
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y , AbeT, SatoY, MatsubaraY, MorikiT, MurataM. Effects of verify now P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: a systematic review and meta-analysis. Platelets24(5) , 352–361 (2012).
   PubMed Web of Science ®Google Scholar
• Singh M , ShahT, AdigopulaS et al. CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful? Indian Heart J.64(4) , 341–352 (2012).
   PubMedGoogle Scholar
• Holmes MV , PerelP, ShahT, HingoraniAD, CasasJP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA306(24) , 2704–2714 (2011).
   PubMed Web of Science ®Google Scholar
• Verschuren JJ , BodenH, WesselsJA et al. Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction. Int. J. Cardiol. 167(6) , 2882–2888 (2012).
   PubMed Web of Science ®Google Scholar
• Carlquist JF , KnightS, HorneBD et al. Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes. Thromb. Haemost. 109(4) , 744–754 (2013).
   PubMed Web of Science ®Google Scholar
• Marcucci R , GiustiB, PanicciaR et al. High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers. Platelets 23(8) , 586–593 (2012).
   PubMed Web of Science ®Google Scholar
• Oh IY , ParkKW, KangSH et al. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart 98(2) , 139–144 (2012).
   PubMed Web of Science ®Google Scholar
• Park JJ , ParkKW, KangJ et al. Genetic determinants of clopidogrel responsiveness in Koreans treated with drug-eluting stents. Int. J. Cardiol. 163(1) , 79–86 (2013).
   PubMed Web of Science ®Google Scholar
• Bhatt DL , PareG, EikelboomJW et al. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur. Heart J. 33(17) , 2143–2150 (2012).
   PubMed Web of Science ®Google Scholar
• Zou JJ , XieHG, ChenSL et al. Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention. Eur. J. Clin. Pharmacol. 69(4) , 771–777 (2013).
   PubMed Web of Science ®Google Scholar
• Jaitner J , MorathT, ByrneRA et al. No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting. Circ. Cardiovasc. Interv. 5(1) , 82–88, S1–S2 (2012).
   PubMed Web of Science ®Google Scholar
• Li Y , TangHL, HuYF, XieHG. The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. J. Thromb. Haemost.10(2) , 199–206 (2012).
   PubMed Web of Science ®Google Scholar
• Harmsze AM , van Werkum JW, Hackeng CM et al. The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet. Genomics22(3) , 169–175 (2012).
   PubMed Web of Science ®Google Scholar
• Close SL . Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant? Fundam. Clin. Pharmacol.26(1) , 19–26 (2012).
   PubMed Web of Science ®Google Scholar
• Terpening C . Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease. Clin. Med. Insights Cardiol.4 , 117–128 (2010).
   PubMedGoogle Scholar
• Su J , XuJ, LiX et al. ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PLoS ONE7(10) , e46366 (2012).
   PubMed Web of Science ®Google Scholar
• Luo M , LiJ, XuX, SunX, ShengW. ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: a meta-analysis. Thromb. Res.129(6) , 754–759 (2012).
   PubMed Web of Science ®Google Scholar
• Degoma EM , RiveraG, LillySM, UsmanMH, MohlerER. Personalized vascular medicine: individualizing drug therapy. Vasc. Med.16(5) , 391–404 (2011).
   PubMed Web of Science ®Google Scholar
• Bouman HJ , SchömigE, van Werkum JW et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med.17(1) , 110–116 (2011).
   PubMed Web of Science ®Google Scholar
• Tselepis AD , TsoumaniME, KalantziKI, DimitriouAA, TellisCC, GoudevenosIA. Influence of high-density lipoprotein and paraoxonase-1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy. J. Thromb. Haemost.9(12) , 2371–2378 (2011).
   PubMed Web of Science ®Google Scholar
• Reny JL , CombescureC, DaaliY, FontanaP. PON1 meta-analysis group. Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis. J. Thromb. Haemost.10(7) , 1242–1251 (2012).
   PubMed Web of Science ®Google Scholar
• Paré G , RossS, MehtaSR et al. Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the clopidogrel in the unstable angina to prevent recurrent events trial and the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Circ. Cardiovasc. Genet. 5(2) , 250–256 (2012).
   PubMed Web of Science ®Google Scholar
• Cayla G , HulotJS, O‘ConnorSA et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA 306(16) , 1765–1774 (2011).
   PubMed Web of Science ®Google Scholar
• Mega JL , CloseSL, WiviottSD et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4) , 354–362 (2009).
   PubMed Web of Science ®Google Scholar
• Brackbill ML , KiddRS, AbdooAD, WarnerJG, HarralsonAF. Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome. Heart Vessels24(2) , 73–78 (2009).
   PubMed Web of Science ®Google Scholar
• Harmsze AM , van Werkum JW, ten Berg JM et al.CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case–control study. Eur. Heart J.31(24) , 3046–3053 (2010).
   PubMed Web of Science ®Google Scholar
• Brandt JT , CloseSL, IturriaSJ et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost. 5(12) , 2429–2436 (2007).
   PubMed Web of Science ®Google Scholar
• Suh JW , KooBK, ZhangSY et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 174(12) , 1715–1722 (2006).
   PubMed Web of Science ®Google Scholar
• Simon T , VerstuyftC, Mary-KrauseM et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360(4) , 363–375 (2009).
   PubMed Web of Science ®Google Scholar
• Motovska Z , KvasnickaJ, HajkovaJ et al. Platelet gene polymorphisms and risk of bleeding in patients undergoing elective coronary angiography: a genetic sub-study of the PRAGUE-8 trial. Atherosclerosis 212(2) , 548–552 (2010).
   PubMed Web of Science ®Google Scholar
• Cooke GE , Liu-StrattonY, FerketichAK et al. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. J. Am. Coll. Cardiol. 47(3) , 541–546 (2006).
   PubMed Web of Science ®Google Scholar
• Lev EI , PatelRT, GuthikondaS, LopezD, BrayPF, KleimanNS. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb. Res.119(3) , 355–360 (2007).
   PubMed Web of Science ®Google Scholar
• Isordia-Salas I , Olalde-RománMJ, Santiago-GermánD, de la Peña NC, Valencia-Sánchez JS. The impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population. Thromb. Res.130(3) , e67–e72 (2012).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ , Fernandez-OrtizA, BernardoE et al. PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagul. Fibrinolysis15(1) , 89–93 (2004).
   PubMed Web of Science ®Google Scholar
• Dropinski J , MusialJ, JakielaB, WegrzynW, SanakM, SzczeklikA. Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta 3 integrin in patients with coronary artery disease not being treated with aspirin. Thromb. Haemost.94(6) , 1300–1305 (2005).
   PubMed Web of Science ®Google Scholar
• Staritz P , KurzK, StollM, GiannitsisE, KatusHA, IvandicBT. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene. Int. J. Cardiol.133(3) , 341–345 (2009).
   PubMed Web of Science ®Google Scholar
• Rudez G , BoumanHJ, van Werkum JW et al. Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions. Circ. Cardiovasc. Genet.2(5) , 515–521 (2009).
   PubMedGoogle Scholar
• Hulot JS , BuraA, VillardE et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108(7) , 2244–2247 (2006).
   PubMed Web of Science ®Google Scholar
• Harmsze A , van Werkum JW, Bouman HJ et al. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenet. Genomics20(1) , 18–25 (2010).
   PubMed Web of Science ®Google Scholar
• Kar R , MeenaA, YadavBK, YadavR, KarSS, SaxenaR. Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms. Platelets24(4) , 297–302 (2012).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ , Fernandez-OrtizA, BernardoE et al. 807 C/T polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment. Blood Coagul. Fibrinolysis 15(5) , 427–433 (2004).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ , Fernandez-OrtizA, BernardoE et al. Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene. Am. J. Cardiol. 96(8) , 1095–1099 (2005).
   PubMed Web of Science ®Google Scholar
• Giusti B , GoriAM, MarcucciR et al. Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment. Atherosclerosis 196(1) , 341–348 (2008).
   PubMed Web of Science ®Google Scholar
• Smith SM , JudgeHM, PetersG et al. PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy. Platelets16(6) , 340–345 (2005).
   PubMed Web of Science ®Google Scholar
• Lewis JP , HorensteinRB, RyanK et al. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet. Genomics 23(1) , 1–8 (2013).
   PubMed Web of Science ®Google Scholar
• Montalescot G , WiviottSD, BraunwaldE et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373(9665) , 723–731 (2009).
   PubMed Web of Science ®Google Scholar
• Alexopoulos D , DimitropoulosG, DavlourosP et al. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150 mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc. Interv. 4(4) , 403–410 (2011).
   PubMed Web of Science ®Google Scholar
• Grosdidier C , QuiliciJ, LoosveldM et al. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. Am. J. Cardiol. 111(7) , 985–990 (2013).
   PubMed Web of Science ®Google Scholar
• Cuisset T , LoosveldM, MorangePE et al. CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome. JACC Cardiovasc. Interv.5(12) , 1280–1287 (2012).
   PubMed Web of Science ®Google Scholar
• Sorich MJ , VitryA, WardMB, HorowitzJD, McKinnonRA. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J. Thromb. Haemost.8(8) , 1678–1684 (2010).
   PubMed Web of Science ®Google Scholar
• Mega JL , CloseSL, WiviottSD et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119(19) , 2553–2560 (2009).
   PubMed Web of Science ®Google Scholar
• Mega JL , CloseSL, WiviottSD et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 376(9749) , 1312–1319 (2010).
   PubMed Web of Science ®Google Scholar
• Wallentin L , BeckerRC, BudajA et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11) , 1045–1057 (2009).
   PubMed Web of Science ®Google Scholar
• Oh EY , AbrahamT, SaadN, RappJH, VasteyFL, BalmirE. A comprehensive comparative review of adenosine diphosphate receptor antagonists. Expert Opin. Pharmacother.13(2) , 175–191 (2012).
   PubMed Web of Science ®Google Scholar
• Tantry US , BlidenKP, WeiC et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ. Cardiovasc. Genet. 3(6) , 556–566 (2010).
   PubMed Web of Science ®Google Scholar
• Wallentin L , JamesS, StoreyRF et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic sub-study of the PLATO trial. Lancet 376(9749) , 1320–1328 (2010).
   PubMed Web of Science ®Google Scholar
• Storey RF , Melissa Thornton S, Lawrance R et al. Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.Platelets20(5) , 341–348 (2009).
   PubMed Web of Science ®Google Scholar
• Scott SA , SangkuhlK, SteinCM et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin. Pharmacol. Ther. 94(3) , 317–323 (2013).
   PubMed Web of Science ®Google Scholar
• Swen JJ , WiltingI, de Goede AL et al. Pharmacogenetics: from bench to byte. Clin. Pharmacol. Ther.83(5) , 781–787 (2008).
   PubMed Web of Science ®Google Scholar
• Roberts JD , WellsGA, Le May MR et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet379(9827) , 1705–1711 (2012).
   PubMed Web of Science ®Google Scholar
• Panattoni L , BrownPM, Te Ao B, Webster M, Gladding P. The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation. Pharmacoeconomics30(11) , 1067–1084 (2012).
   PubMed Web of Science ®Google Scholar
• Crespin DJ , FederspielJJ, BiddleAK, JonasDE, RossiJS. Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost–effectiveness analysis. Value Health14(4) , 483–491 (2011).
   PubMed Web of Science ®Google Scholar
• ten Berg JM , DeneerVH. Antiplatelet therapy: does CYP2C19 genotype affect clinical outcome? Nat. Rev. Cardiol.9(4) , 192–194 (2012).
   PubMed Web of Science ®Google Scholar
• Shuldiner AR , O‘ConnellJR, BlidenKP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302(8) , 849–857 (2009).
   PubMed Web of Science ®Google Scholar
• Geisler T , SchaeffelerE, DipponJ et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics9(9) , 1251–1259 (2008).
   PubMed Web of Science ®Google Scholar

▪ Websites

• EMA. www.ema.europa.eu/ema/
   Google Scholar
• ClinicalTrials.gov. http://clinicaltrials.gov/ct2/home
   Google Scholar